The poor response rates of RAS and PTPN11-mutated AML patients to venetoclax-based therapies suggest that for these patients, conventional chemotherapy is the best treatment option and in order to increase response rates other additional therapy, MCL-1 or MEK1/2 inhibitors [101,102] could be a future treatment strategy. Here, MAP2K1 is linked to acute myeloid leukemia.